Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Jennifer E Amengual"'
Autor:
Xiao Chen, Yinglu Li, Fang Zhu, Xinjing Xu, Brian Estrella, Manuel A. Pazos, John T. McGuire, Dimitris Karagiannis, Varun Sahu, Mustafo Mustafokulov, Claudio Scuoppo, Francisco J. Sánchez-Rivera, Yadira M. Soto-Feliciano, Laura Pasqualucci, Alberto Ciccia, Jennifer E. Amengual, Chao Lu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Interplay between chromatin-associated complexes and modifications critically contribute to the partitioning of epigenome into stable and functionally distinct domains. Yet there is a lack of systematic identification of chromatin crosstalk
Externí odkaz:
https://doaj.org/article/daa06f01dba548f4b57a4bb4e1ae71da
Autor:
Yun Kyoung Ryu, Edd C. Ricker, Craig R. Soderquist, Mark A. Francescone, Andrew H. Lipsky, Jennifer E. Amengual
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 16, p 4928 (2022)
Plasmablastic lymphoma (PBL) is a rare and aggressive form of large B-cell lymphoma (LBCL) most commonly seen in the setting of chronic immunosuppression or autoimmune disease. The prognosis is poor and CHOP-like regimens often fail to produce durabl
Externí odkaz:
https://doaj.org/article/01ab186be35d4831bd9e452a718b6a63
Autor:
Connie Lee Batlevi, Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Manu Sondhi, Yingxue Chen, Pamela L. Slatcher, Richard Lin, Attila Szanto, Sara Abbadi, Franck Morschhauser
Publikováno v:
Blood. 140:2296-2298
Autor:
Alexander Coltoff, Andrew H. Lipsky, Todd L. Rosenblat, Jennifer E. Amengual, Mark L Heaney, Joseph G. Jurcic, Nicole Lamanna
Publikováno v:
Blood. 140:9893-9895
Autor:
Lorenzo Falchi, Ahmed Sawas, Changchun Deng, Jennifer E. Amengual, Donald S. Colbourn, Emily A. Lichtenstein, Karen A. Khan, Lawrence H. Schwartz, Owen A. O’Connor
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-4 (2016)
Abstract Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in this populat
Externí odkaz:
https://doaj.org/article/6eaa84f816364138979c03d00820a0cb
Autor:
Owen A. O'Connor, Olivier Elemento, Akanksha Verma, Serge Cremers, Renu Nandakumar, Jimmy Duong, Ying Wei, Xavier Jirau Serrano, Luigi Scotto, Yulissa Gonzalez, Paul M. Johannet, Kelly Zullo, Maximilian Lombardo, Sathyen A. Prabhu, Jennifer E. Amengual
Purpose: Pan-class I/II histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. ACY-1215 (ricolinostat) is a first-in-class selective HDA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b94422791cde262884e5e71d6e884a0
https://doi.org/10.1158/1078-0432.c.6525519.v1
https://doi.org/10.1158/1078-0432.c.6525519.v1
Autor:
Owen A. O'Connor, Daruka Mahadevan, Jimmy Duong, Serge Cremers, Renu Nandakumar, Yinghui Mao, Jennifer E. Amengual, Luigi Scotto, Michael Mangone, Xavier Jirau-Serrano, Laurence Cooke, Yige Guo, Kelly M. Zullo
Purpose: Aurora A kinase (AAK) is expressed exclusively during mitosis, and plays a critical role in centrosome duplication and spindle formation. Alisertib is a highly selective AAK inhibitor that has demonstrated marked clinical activity of alisert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::518812210463516dac33e39bd5882431
https://doi.org/10.1158/1078-0432.c.6523485.v1
https://doi.org/10.1158/1078-0432.c.6523485.v1
Autor:
Owen A. O'Connor, Susan E. Bates, Ronald Realubit, Charles Karan, Changchun Deng, Jennifer E. Amengual, Govind Bhagat, Yuan Zhang, Ying Wei, Tiffany Thomas, Serge Cremers, Kenneth P. Olive, Stephen A. Sastra, Carmine F. Palermo, Luigi Scotto, Kelly M. Zullo, Xavier Jirau-Serrano, Salvia Jain
Purpose: T-cell lymphomas (TCL) are aggressive diseases, which carry a poor prognosis. The emergence of new drugs for TCL has created a need to survey these agents in a rapid and reproducible fashion, to prioritize combinations which should be priori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd2dfddf7581dd54f3a7709c025e733
https://doi.org/10.1158/1078-0432.c.6524241.v1
https://doi.org/10.1158/1078-0432.c.6524241.v1
Data from Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Autor:
Jennifer E. Amengual, Olivier Elemento, Neil L. Kelleher, Serge Cremers, Renu Nandakumar, Changhong Qiao, Emily I. Chen, Swasti Mehta, Jeannie M. Camarillo, Nebiyu Abshiru, Prabhjot S. Mundi, Akanksha Verma, Yulissa Gonzalez, Yuxuan Liu, Sathyen A. Prabhu, Jennifer K. Lue
Purpose:Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC)–derived lymphomas. We hypot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c25494f751d349c18a9a0f314e919e
https://doi.org/10.1158/1078-0432.c.6527655
https://doi.org/10.1158/1078-0432.c.6527655
Autor:
Owen A. O'Connor, Simon Jones, Yuan Zhang, Serge Cremers, Hongfeng Jiang, Jennifer Heinen, Dejan Radeski, Xavier Jirau-Serrano, Luigi Scotto, Govind Bhagat, Daniela Hoehn, Kelly Zullo, Maximilian Lombardo, Paul Johannet, Jennifer E. Amengual
Purpose: Pan-class histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. HDAC6 is a class IIb deacetylase that facilitates misfolded pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65c138e0e4b7e1256e44af768ef5d82
https://doi.org/10.1158/1078-0432.c.6524379.v1
https://doi.org/10.1158/1078-0432.c.6524379.v1